GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (STU:0OP) » Definitions » Debt-to-EBITDA

OptiNose (STU:0OP) Debt-to-EBITDA : -3.64 (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is OptiNose Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

OptiNose's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.67 Mil. OptiNose's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €120.20 Mil. OptiNose's annualized EBITDA for the quarter that ended in Mar. 2024 was €-33.17 Mil. OptiNose's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -3.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for OptiNose's Debt-to-EBITDA or its related term are showing as below:

STU:0OP' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.56   Med: -1.5   Max: 0.58
Current: -12.56

During the past 9 years, the highest Debt-to-EBITDA Ratio of OptiNose was 0.58. The lowest was -12.56. And the median was -1.50.

STU:0OP's Debt-to-EBITDA is ranked worse than
100% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs STU:0OP: -12.56

OptiNose Debt-to-EBITDA Historical Data

The historical data trend for OptiNose's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiNose Debt-to-EBITDA Chart

OptiNose Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.76 -1.54 -1.99 -2.28 -8.47

OptiNose Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.32 4.33 -7.70 -6.93 -3.64

Competitive Comparison of OptiNose's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OptiNose's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where OptiNose's Debt-to-EBITDA falls into.



OptiNose Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

OptiNose's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(120.254 + 0.56) / -14.262
=-8.47

OptiNose's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.667 + 120.201) / -33.172
=-3.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


OptiNose  (STU:0OP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


OptiNose Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of OptiNose's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


OptiNose (STU:0OP) Business Description

Comparable Companies
Traded in Other Exchanges
Address
1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

OptiNose (STU:0OP) Headlines

No Headlines